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Microsatellite instability (MSI) is the molecular hallmark of DNA mismatch repair deficiency.
Since its initial description in colorectal cancer (CRC) in 1993 and its association with Lynch
syndrome, the most common inherited cancer predisposition world-wide, accumulating
evidence suggests that MSI status may also be of concrete prognostic and predictive
value in the management of sporadic CRC. This mini review aims at providing a concise
survey of the molecular basis and the multifaceted role(s) of MSI status in today’s clinical
practice.
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INTRODUCTION
Twenty years ago, in 1993, in search for molecular clues to the
pathogenesis of colorectal cancer (CRC) several research groups
had made an intriguing observation: widespread somatic alter-
ations at short, repetitive DNA sequences, referred to as replication
error (RER+) phenotype or, more specifically, microsatellite insta-
bility (MSI) (1–3). They detected this novel form of genomic
instability in about 10–15% of sporadic, predominantly proxi-
mally located, colorectal carcinomas as well as in most (>90%) of
those from patients with the most common inherited cancer pre-
disposition, Lynch syndrome (LS), also referred to as Hereditary
Non-Polyposis Colon Cancer (HNPCC). The discovery allowed to
link the hereditary disorder to a defect in a key DNA metabolic
pathway, the mismatch repair (MMR) system, which had previ-
ously been known to cause MSI in Saccharomyces cerevisiae, and
eventually opened up a new field in cancer research (4).
THE MOLECULAR BASIS OF MSI
Microsatellites, also referred to as short tandem repeats (STRs),
consist of a few to several thousands of tandemly repeated motifs
made up of one (mono) up to six (hexa) nucleotides and are
thought to account for approximately 3% of the human genome
(5). Given their number and the fact that they are scattered
throughout the genome, their (hyper)variability in length coupled
with a high degree of heterozygosity made them ideal polymorphic
markers for genome mapping, population genetics, and genetic
linkage studies as well as indispensable tools in forensics and
transplantation medicine (“DNA fingerprint”).
Due to their repetitive sequence structure, it is not surpris-
ing that microsatellites exhibit a particularly high mutation rate
compared to non-repetitive, unique DNA stretches. During repli-
cation of the nuclear genome DNA polymerases, due to slip-
page, often fail to correctly duplicate such microsatellite tracts.
The resulting insertion/deletion loops can consequently lead to
insertions or deletions of repeats, thereby altering the length of
the respective microsatellite (replication error, RER). In eukary-
otes these errors are corrected by the DNA MMR system: its
heterodimers MSH2/MSH6 and MSH2/MSH3 detect the replica-
tion error (licensing step) and recruit the MLH1/PMS2 complex
through which degradation of the mutated stretch and resynthesis
are initiated (4). As originally observed in yeast, defects in MMR
consequently result in the genome-wide accumulation of muta-
tions at microsatellite loci, MSI, which has also been referred to as
a “mutator phenotype” (6).
ASSESSMENT OF MSI
Since MSI analysis of colorectal tumors provided a straight-
forward, though indirect, means to identify LS patients great
attention was given to the development of selection criteria and
microsatellite markers to be used for testing. In 1996 and 2002
the National Cancer Institute in Bethesda, MD, held workshops in
which the Bethesda guidelines for the identification of LS patients
were defined (7, 8). MSI testing is recommended in patients
who meet one of the following criteria: (a) diagnosed with CRC
before age 50 years, (b) synchronous or metachronous CRC or
other LS-related tumors, (c) CRC with typical MSI-high mor-
phology and diagnosed before age 60 years, (d) CRC in one or
more first-degree relatives with CRC or other LS-related tumors,
one being diagnosed before age 50 years, and (e) CRC with two or
more relatives with CRC or other LS-related tumors, regardless of
age. The revised Bethesda guidelines thus incorporate personal as
well as family history and pay attention to the fact that LS actu-
ally comprises a spectrum of different tumor types (endometrial,
gastric, etc.).
To assess the presence of MSI in a given tumor the NCI
workshop recommended to analyze a panel of five microsatel-
lites including two mono- (BAT25, BAT26) and three di-
nucleotide markers (D2S123, D5S346, and D17S250); depending
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on the mutational pattern, a secondary panel including addi-
tional mononucleotide (e.g., BAT40) and/or complex microsatel-
lites (e.g., MYCL) should be tested (8). Alternatively, a panel
of five quasimonomorphic mononucleotide repeats can be used
which display even better sensitivity and which may obviate the
need for normal tissue for comparison (9). Depending on the
number of microsatellite markers displaying novel alleles, MSI
can subsequently be rated as MSI-high (MSI-H, >2 out of 5
markers), MSI-low (MSI-L, 1 out of 5), or microsatellite stable
(MSS, 0 out of 5).
The molecular dissection of CRCs into MSI-H and MSS tumors
allowed to delineate two major, virtually exclusive pathways of
genetic instability: chromosomal instability, which results in ane-
uploidy and is present in about 85% of CRC, and MSI. Whether
MSI-L CRC constitute a pathogenetic class of their own is still
a matter of debate: with regard to clinical, biological, and mor-
phological parameters they closely resemble those of MSS CRC.
Since the analytical sensitivity to detect MSI-L is dependent on the
number of microsatellite markers analyzed, result interpretation,
and comparison between different studies investigating MSI-L
and MSS tumors are heavily compromised; furthermore, exten-
sive genotyping efforts have failed to demonstrate fundamental
differences (10, 11). Given these unresolved issues, a molecular
subdivision into MSI-L and MSS CRC does currently not seem
appropriate.
ROLE OF MSI IN LYNCH SYNDROME
The discovery of MSI in the majority of LS-related CRC led by
analogy to a similar biochemical defect in yeast to the identifi-
cation of the underlying MMR germ line mutations in MLH1,
MSH2, MSH6, and PMS2. Heterozygous carriers of a MMR gene
alteration are at a greatly increased lifetime risk to develop cancers
of the LS tumor spectrum, mainly CRC (25–70%) and endome-
trial cancer (30–70%) (12). Knowledge of the underlying germ line
mutation not only allows life-saving intensive-cancer surveillance
but also gives asymptomatic family members the opportunity to
clarify their carrier status; due to autosomal dominant inheritance
offspring of a LS patient has an a priori chance of 50% of having
inherited the pathogenic MMR mutation.
In contrast to their sporadic MSS CRC LS patients’ tumors
typically have a comparatively favorable prognosis and absence
of distant organ metastasis; together with the observation that LS
cancers are accompanied by an intense immune response with
dense lymphocytic infiltrates points to a possible protective effect
by the immune system (13).
The revised Bethesda guidelines are probably the most com-
monly applied criteria to identify individuals with LS, yet many
physicians dealing with familial CRC have the impression that LS
per se remains underdiagnosed (14). An expert group therefore
recently suggested to screen all individuals with CRC or endome-
trial cancer below age 70 by immunohistochemistry or MSI, both
of which having similar clinical sensitivity and specificity. In order
to discriminate between a hereditary (about 2–3% of all CRC) or
a sporadic event (about 15%), tumors with immunohistochemi-
cal loss of MLH1 should then be further investigated for MLH1
promoter hypermethylation and targeted BRAF (V600E hotspot
mutation) testing to decide on further (germ line) genetic testing.
With high-throughput sequencing techniques entering routine
genetic testing it is likely that these diagnostic screening algorithms
will considerably change in the foreseeable future (15).
ROLE OF MSI IN SPORADIC CANCER
Since their initial description it became evident that the 15% of
sporadic MSI-H CRCs exhibit a distinct clinico-pathological pro-
file, which they largely share with LS-related CRC and which dis-
tinguishes them from their MSS counterparts (Figure 1). Already
in the seminal work by Thibodeau et al. (2) MSI-H CRC were
predominantly located in the proximal colon and associated with
increased patient survival and prognosis (2). Most of them were
later found to exhibit loss of MLH1 protein expression which could
be attributed to epigenetic silencing of the respective promoter,
later also referred to as “CpG island methylator phenotype” since
it often occurs in the context of global hypermethylation (16, 17).
Regarding their molecular-histopathological profile MSI-H CRC
display a diploid state, tend to be poorly differentiated, mucinous,
and show prominent lymphocytic infiltration (15).
A recent meta-analysis by Guastadisegni et al. who pooled data
from 31 studies reporting survival in 12782 patients confirmed
the initial observations between MSI-H status and a more favor-
able prognosis: patients with stages I-IV MSI-H CRC appeared to
have a statistically significantly better outcome in terms of over-
all survival, disease-specific as well as disease-free survival (18).
Moreover, results from a recent Norwegian study have shown that
MSI status had an independent positive prognostic impact on stage
II CRC patients after complete resection (19). How these findings
and the inclusion of additional molecular markers may eventually
impact on routine clinical and surgical practice, however, remains
to be seen.
Guastadisegni et al. also investigated the effect of standard, 5-
fluoro-uracil (5-FU) based chemotherapy. In the context of MSI
and an underlying (hereditary or sporadic) defect in MMR the
use of 5-FU in MSI-H CRC merits particular attention: as demon-
strated in numerous in vitro studies, inactivation of the MMR
system can result in resistance, or rather tolerance (i.e., failure
FIGURE 1 |The role of microsatellite instability (MSI) status in clinical
management of colorectal cancer patients. 5-FU denotes 5-fluoro-uracil.
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to induce cell-cycle arrest), to 5-FU treatment (4, 20). In line
with these observations the meta-analysis found a clear significant
beneficial effect of 5-FU therapy in patients with MSS CRC only.
Further studies by Des Guetz et al. (meta-analysis) and Sargent et
al. provided comparable findings in that relapse-free survival was
similar for treated and untreated MSI-H patients demonstrating
MSI-H status as a predictive factor of non-response to adjuvant,
mostly 5-FU-based chemotherapy (21, 22). The high variability
in treatment response observed in the MSI-H CRC group may
actually reflect the (in) efficiency of other DNA repair systems,
like base-excision repair, to repair/tolerate chemotherapy-induced
DNA lesions. Overall, current data advocate CRC patient stratifi-
cation by determining the tumor’s MMR status, either by testing
for MSI or immunohistochemical analysis of MMR proteins, in
order to decide on adjuvant chemotherapy on an individual basis.
CONCLUDING REMARKS
As exemplified by the rapidly growing list of cancer genomes ana-
lyzed by means of ever more complete as well as cost-effective
high-throughput (“next generation”) sequencing methods, a novel
era of truly personalized medicine seems to be at hand (23). It is
the hope of the author that, despite the inherent difficulties and
(data) challenges when trying to get a deeper understanding of
biological systems as complex as cancer, the novel “omics” and
systems biology approaches will not only allow more comprehen-
sive insights into tumor biology but eventually result in individual
patient (tumor)-tailored treatment and, last not least, enable true
cancer prevention.
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